Vanguard High Dividend Yield ETF vs 22nd Century Group Inc — how do they compare? Vanguard High Dividend Yield ETF trades at $158.88 (market cap $100.80B), while 22nd Century Group Inc trades at $0.8 (market cap $621.67K). The key difference: Vanguard High Dividend Yield ETF is far larger — about 162143.9× 22nd Century Group Inc's market cap, and Vanguard High Dividend Yield ETF is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard High Dividend Yield ETF for 139 Days and 22nd Century Group Inc for 32 Days on average.
| VYM | XXII | |
|---|---|---|
Market Cap | $100.80B | $621.67K |
Volume | 908,176 | 45,625 |
52-Week High | $167.03 | $483.00 |
52-Week Low | $137.47 | $0.80 |
Typical Hold Time | 139 Days | 32 Days |
Sector | — | Consumer Staples |
Enterprise Value | — | -$3.69M |
Signals from Pluang's Aura AI — not financial advice
VYM trades at $158.76, up 0.83% with a bearish technical signal. The ETF faces mixed sentiment as articles highlight its consistent dividend yield of 2.42% but note underperformance versus peers like SCHD. Support levels cluster near $156-157, while resistance sits at $159-160. Recent news questions VYM's stock selection methodology after dividend cuts in holdings like Intel and Walgreens.
Outlook remains cautious due to technical bearishness and competitive pressure from higher-yielding alternatives. Risks include concentrated exposure to dividend-cut vulnerabilities and inflation persistence. Opportunities lie in Vanguard's low-cost, diversified approach for income-focused investors, though superior total return potential exists elsewhere.
22nd Century Group (XXII) trades at $0.89, down 0.94% today, with a bearish technical signal despite oversold RSI readings. The company shows severe financial stress with negative gross margins of -54.6% and net income margin of -76.01%, though valuation metrics appear low with P/S of 0.09 and P/B of 0.03. Recent news highlights regulatory progress in nicotine reduction initiatives and expanded retail distribution for VLN products.
While analyst consensus remains bullish with 75% buy ratings and a $1,240 price target, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock presents high-risk speculation on regulatory adoption of reduced-nicotine standards, requiring careful risk assessment given the company's ongoing losses and cash burn.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →